Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
On-road driving performance with JZP-110 (solriamfetol) in obstructive sleep apnea patients with excessive sleepiness
2015-003930-28Phase 2Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- May 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of solriamfetol in obstructive sleep apnea hypopnea syndrome (OSAHS) and Excessive Daytime Sleepiness (EDS) (2 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoint: Primary Efficacy Endpoint. Started May 2018; status: completed.
02
Drugs
solriamfetol
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)Excessive Daytime Sleepiness (EDS)
Beyond the preview
Go deeper on 2015-003930-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003930-28.